Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...
More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of ...
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...
INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal ...
The US Food and Drug Administration (FDA) has granted approval for Boehringer Ingelheim's SPEVIGO injection to treat generalised pustular psoriasis (GPP). The treatment is indicated for use in adult ...
The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...
The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den ...
She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...
Boehringer Ingelheim and Takeda are the only two pharmaceutical groups to be named among the 15 Global Top Employers for 2023, an award dedicated to companies that enrich the workplace environment.
Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...
Der Börsenhype rund um die sogenannten Fettweg-Spritzen ist ungebrochen. Jetzt rückt ein neuer Kandidat in der Fokus der Investoren. Genau wie beim Börsenstar Novo Nordisk handelt es sich um ...